MDxHealth acquires NovioGendix

New share capital amount and new number of shares

22-Sep-2015 - MDxHealth SA announced that it succesfully completed the acquisition of all of the shares in NovioGendix Holding B.V.. The completion of the acquisition took place on September 18, 2015. As part of the consideration that was paid for the shares in NovioGendix, the Company issued 1,086,956 new ...

MDxHealth's ConfirmMDx Genes Detect Clinically Significant Prostate Cancer

03-Mar-2015 - MDxHealth SA announced that data demonstrating the prognostic value of its ConfirmMDx® for Prostate Cancer genes and technology was presented at the ASCO Genitourinary Cancers Symposium 2015. The data support the ability to predict the presence of clinically significant cancer in biopsy-negative ...

Ghent University and MDxHealth Collaborate to Establish a Center in Pharmaco (Epi)genomics

04-Dec-2012 - MDxHealth SA announced that it has joined forces with the Ghent University to establish NXTGNT, a new Center in Pharmaco (Epi)genomics.The mission of the Center is to accelerate innovation in personalized medicine by using advanced technology, knowledge and expertise in (epi)genetics. The Center ...

MDxHealth Receives CLIA Certification and California State License for its Clinical Laboratory

25-Jan-2012 - MDxHealth SA announced that its state-of-the-art, 13,448 sq.ft clinical laboratory facility in Irvine, California has received Clinical Laboratory Improvements Amendments (CLIA) certification of registration from the Centers for Medicare and Medicaid Services (CMS). In addition, MDxHealth’s ...

MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award

11-Jan-2012 - MDxHealth SA announced the receipt of the Frost & Sullivan 2011 European Molecular Diagnostics for Oncology Technology Leadership award. In giving the awards, Frost & Sullivan recognizes the strength and broad applicability of MDxHealth’s epigenetic technology platform in generating advanced ...

MDxHealth establishes US CLIA laboratory in Irvine, CA, and makes key hires to expand US team

22-Aug-2011 - MDxHealth SA announced that it has signed a lease agreement for a state-of-the-art laboratory and office facilities in Irvine, CA and has filed for CLIA certification of the US site. In addition, MDxHealth has filed for CLIA certification of its Liege facility. The two-pronged commercialization ...

MDxHealth Receives USD 1.1 Million European Grant to Progress Bladder Cancer Program

05-May-2011 - MDxHealth SA announced that together with partner NovioGendix B.V., a molecular diagnostics company spun out from Radboud University Nijmegen Medical Centre (RUNMC), has received a USD 1.1 million grant from Eurotrans-Bio to progress its bladder cancer program. Eurotrans-Bio is a European ...

MDxHealth Appoints New Scientific Advisory Board

28-Mar-2011 - MDxHealth SA announced that it has appointed a Scientific Advisory Board (SAB) to support the Company's management in their new strategy. The SAB members will assist management in the development of current pipeline programs, as well as advise on new directions for the application of MDxHealth's ...

MDxHealth Licenses Methylation Technology to Takara Bio Inc. for Scientific Research Market

30-Nov-2010 - MDxHealth SA announced that it has granted a non-exclusive worldwide license for its patented methylation specific PCR (MSP) technology to Takara Bio Inc.. Under the agreement, Takara Bio Inc. (Takara) has licensed the use of MDxHealth's MSP technology, the most widely applied methylation ...

MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences

23-Nov-2010 - MDxHealth SA announced that it has agreed to out-license certain DNA methylation biomarkers to Predictive Biosciences for diagnostic applications in bladder cancer. Under the agreement, MDxHealth grants Predictive Biosciences exclusive rights for the use of a number of its DNA methylation ...